Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044915 · ClinicalTrials.gov registry record · Phase 2
Repinotan in Patients With Acute Ischemic Stroke
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 782
- Enrollment target
NCT00044915: Completed Phase 2 study, sponsored by Bayer.
NCT00044915 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 782 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (488% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044915, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 782 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.
Interventions
- DRUG Placebo
- DRUG Repinotan HCl (BAYX3702)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 782 participants |
| Start Date | 2000-12 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00044915 record still lists
NCT00044915 is an interventional study that assigns participants to a tested intervention. The registered 782 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (488% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00044915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00044915 about?
NCT00044915 is a clinical study titled "Repinotan in Patients With Acute Ischemic Stroke". The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.
What is the current status of trial NCT00044915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 782 participants. The study started on 2000-12. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00044915?
The interventions under investigation include: Placebo (DRUG), Repinotan HCl (BAYX3702) (DRUG).
Who is sponsoring clinical trial NCT00044915?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00044915's enrollment target sits among peer trials
782 41st of 2000 higher than 1,960 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06575192 · 783 participants · Phase 3
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia